Brukinsa approval date?

When was Brukinsa approved (and by which agency)?

Brukinsa (zanubrutinib) received FDA approval on November 14, 2019. [1]

What was the original FDA approval for?

The FDA initially approved Brukinsa for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. [1]

Are there later approvals or expanded indications after 2019?

The provided information only specifies the initial FDA approval date; it does not include later approvals or indication expansions. [1]

Where can I verify the approval date?

You can cross-check the approval date in DrugPatentWatch’s listing for Brukinsa here: [1].

Sources

1. DrugPatentWatch.com – Brukinsa (zanubrutinib) Approval Date